Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis
- PMID: 15851026
- DOI: 10.1016/j.cell.2005.02.031
Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis
Abstract
Tuberous sclerosis (TSC) is a tumor syndrome caused by mutation in TSC1 or TSC2 genes. TSC tumorigenesis is not always accompanied by loss of heterozygosity (LOH). Recently, extracellular signal-regulated kinase (Erk) has been found activated in TSC lesions lacking TSC1 or TSC2 LOH. Here, we show that Erk may play a critical role in TSC progression through posttranslational inactivation of TSC2. Erk-dependent phosphorylation leads to TSC1-TSC2 dissociation and markedly impairs TSC2 ability to inhibit mTOR signaling, cell proliferation, and oncogenic transformation. Importantly, expression of an Erk nonphosphorylatable TSC2 mutant in TSC2+/- tumor cells where Erk is constitutively activated blocks tumorigenecity in vivo, while wild-type TSC2 is ineffective. Our findings position the Ras/MAPK pathway upstream of the TSC complex and suggest that Erk may modulate mTOR signaling and contribute to disease progression through phosphorylation and inactivation of TSC2.
Similar articles
-
Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.Cancer Res. 2007 Aug 1;67(15):7106-12. doi: 10.1158/0008-5472.CAN-06-4798. Cancer Res. 2007. PMID: 17671177
-
Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.J Cell Biol. 2002 Oct 28;159(2):217-24. doi: 10.1083/jcb.jcb.200206108. Epub 2002 Oct 28. J Cell Biol. 2002. PMID: 12403809 Free PMC article.
-
Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13489-94. doi: 10.1073/pnas.0405659101. Epub 2004 Sep 1. Proc Natl Acad Sci U S A. 2004. PMID: 15342917 Free PMC article.
-
The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.Novartis Found Symp. 2004;262:148-54; discussion 154-9, 265-8. Novartis Found Symp. 2004. PMID: 15562827 Review.
-
Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.Cancer Biol Ther. 2003 Sep-Oct;2(5):471-6. doi: 10.4161/cbt.2.5.446. Cancer Biol Ther. 2003. PMID: 14614311 Review.
Cited by
-
A comprehensive small interfering RNA screen identifies signaling pathways required for gephyrin clustering.J Neurosci. 2012 Oct 17;32(42):14821-34. doi: 10.1523/JNEUROSCI.1261-12.2012. J Neurosci. 2012. PMID: 23077067 Free PMC article.
-
S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer.PLoS One. 2011;6(11):e27509. doi: 10.1371/journal.pone.0027509. Epub 2011 Nov 15. PLoS One. 2011. PMID: 22110663 Free PMC article.
-
Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus.Sci Signal. 2012 Oct 23;5(247):ra77. doi: 10.1126/scisignal.2003199. Sci Signal. 2012. PMID: 23092893 Free PMC article.
-
mTOR, a new potential target for chronic pain and opioid-induced tolerance and hyperalgesia.Mol Pain. 2015 May 30;11:32. doi: 10.1186/s12990-015-0030-5. Mol Pain. 2015. PMID: 26024835 Free PMC article. Review.
-
Regulation of mTORC1 and its impact on gene expression at a glance.J Cell Sci. 2013 Apr 15;126(Pt 8):1713-9. doi: 10.1242/jcs.125773. Epub 2013 May 2. J Cell Sci. 2013. PMID: 23641065 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous